---
title: "海思科製藥獲得重症肌無力藥物試驗的許可"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/264134306.md"
description: "海思科獲得重症肌無力藥物試驗批准"
datetime: "2025-11-04T04:05:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264134306.md)
  - [en](https://longbridge.com/en/news/264134306.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264134306.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/264134306.md) | [English](https://longbridge.com/en/news/264134306.md)


# 海思科製藥獲得重症肌無力藥物試驗的許可



### 相關股票

- [海思科 (002653.CN)](https://longbridge.com/zh-HK/quote/002653.CN.md)

## 相關資訊與研究

- [海思科獲得創新藥 HSK39297 片上市許可《受理通知書》](https://longbridge.com/zh-HK/news/278254470.md)
- [海思科：HSK50042 片新增適應症取得臨牀試驗批准](https://longbridge.com/zh-HK/news/277900704.md)
- [復宏漢霖治療實體瘤藥物臨牀試驗申請獲國家藥監局批准](https://longbridge.com/zh-HK/news/278358313.md)
- [政府欲拿藥價差支持本土藥廠 藥師籲配套：確保一定比率「藥留台灣」](https://longbridge.com/zh-HK/news/278220323.md)
- [石藥集團新藥獲準美國開展臨牀試驗，適應症為肺纖維化](https://longbridge.com/zh-HK/news/278294701.md)